BC Week In Review | Dec 3, 2012
Company News

Smith & Nephew, DFB deal

Smith & Nephew will acquire DFB's Healthpoint Biotherapeutics subsidiary for $782 million in cash. Smith & Nephew, which plans to integrate Healthpoint into its advanced wound management division, said Healthpoint will provide a range of...
BC Extra | Nov 29, 2012
Company News

Smith & Nephew to acquire DFB dermatology subsidiary

Smith & Nephew plc (LSE:SN; NYSE:SNN) will acquire the Healthpoint Biotherapeutics subsidiary of DFB Pharmaceuticals Inc. (Fort Worth, Texas) for $782 million in cash. Smith & Nephew, which plans to integrate Healthpoint into its Advanced...
BC Week In Review | Oct 11, 2010
Clinical News

Collagenase Santyl: Post-marketing study data

DFB's Healthpoint Ltd. subsidiary reported data from a post-marketing study in 27 patients showing that topical Collagenase Santyl ointment significantly increased the proportion of patients experiencing complete debridement of their pressure ulcers by day 42...
BC Week In Review | Sep 6, 2010
Clinical News

Collagenase Santyl: Phase IV started

DFB's HealthPoint Ltd. subsidiary began a double-blind, placebo-controlled, U.S. Phase IV trial to evaluate topical Collagenase Santyl vs. white petrolatum for 4 weeks in 100 patients. Healthpoint purchased the topical collagenase business from BioSpecifics Technologies...
BC Week In Review | Feb 1, 2010
Company News

DFB sales and marketing update

DFB's Healthpoint Ltd. subsidiary launched Collagenase Santyl ointment in Canada for the debridement of chronic dermal ulcers and severely burned areas. Healthpoint purchased the topical collagenase business from BioSpecifics Technologies Corp. (NASDAQ:BSTC, Lynbrook, N.Y.) in...
BC Week In Review | Sep 1, 2008
Clinical News

Collagenase Santyl: Pilot trial start

DFB’s Healthpoint Ltd. subsidiary began a double-blind, U.S. pilot trial in 30 healthy volunteers to compare Collagenase Santyl and white petrolatum ointment. The product is approved for debriding chronic dermal ulcers and severely burned areas....
BC Week In Review | Feb 7, 2000
Company News

BioSpecifics, Smith & Nephew, Knoll sales and marketing update

SNN acquired exclusive North American marketing rights from Knoll to BSTC's Collagenase Santyl Ointment, which is approved to debride chronic dermal ulcers and severely burned areas. BSTC said 1999 North American Collagenase sales exceeded $37...
BioCentury | Feb 7, 2000
Finance

Another (yawn) $billion IPO

Antigenics (AGEN) on Friday put its emphatic exclamation mark on the exploding biotech IPO market, pricing 3.5 million shares at $18 and then watching them skyrocket $43.375 (241 percent) to $61.375 on 5.2 million shares....
BC Week In Review | Dec 11, 1995
Clinical News

Collagenase Santyl ointment data

BSTC completed clinical trials in Italy for the re-registration of its collagenase ointment, which is marketed in the U.S. New trials were necessary to reintroduce the product in Italy after BSTC's agreement with its prior...
BC Week In Review | Mar 13, 1995
Clinical News

Powdered collagenase: Will start a Phase II trial within the month, with partner Knoll Pharmaceutical Co., enrolling a maximum of 180 patients

BioSpecifics Technologies Corp. (BSTC), Lynbrook, N.Y.   Product: Powdered collagenase , which is applied in a higher concentration and works more quickly than the approved ointment (BSTC's Collagenase Santyl )   Indication: Non-surgical, rapid debridement of dead...
Items per page:
1 - 10 of 13